T h e normal CNS is often referred to as an immunologically privileged site. Two of the more important factors contributing to this are as follows. First, the CNS is, in most places, 'encapsulated' within the blood-brain barrier (BBB) formed by specialized endothelium whose basement membrane is in contact with glial cells of this tissue [astrocytes and some microglia (MG)]. As a consequence, the CNS contains few blood-derived leucocytes (including T-cells) , which normally are unable to bypass this barrier [1, 2] . Secondly, the expression of products of the MHC required for T-cell recognition of peptide antigen are absent or at very low level in the CNS (particularly MHC class I1 expression) [3]. Thus it is not immediately apparent how the cells of the immune system access the CNS, and for the T-cells, even if they do, how and where antigen recognition occurs to enable activation and effector function to be elicited. Nevertheless, the development of CD4' T-cell-mediated inflammatory disease of the CNS [4] , such as in experimental autoimmune encephalomyelitis (EAE), Abbreviations used: CNS, central nervous system; BBB, blood-brain barrier; MG, microglia; EAE, experimental autoimmune encephalomyelitis; APC, antigen-presenting cell; MBP, myelin basic protein; PVC, perivascular cells; GvHD, graft-versus-host disease; IL, interleukin; IFN, interferon. indicates directly that T-cells can access the CNS, recognize antigen and instigate an inflammatory response there.
We now know that the structural and immunological barriers in the CNS can be circumvented in a way that normally enables immunological surveillance to be performed but at the same time probably limits excess immunological activation in a tissue that cannot afford to be inflamed or suffer substantial tissue damage. Indeed the evidence now points to a default pathway that shuts down rather than maintains T-cell responses, at least of those type 1 CD4' T-cell responses potentially most damaging to tissues [51.
Traffic of T-cell blasts and MHC expression in the CNS
Activated CD4' T-cells are capable of crossing the BBB and entering the CNS; most importantly, this process is an antigen non-specific one. Resting CD4' T-cells are unable to pass through the BBB [2, 6] . What this means is that it is only those relatively few T-cells recently activated (for example to an infectious agent) in lymphoid tissue outside the CNS that access the healthy CNS. If antigen is detected on crossing the BBB, some response is elicited. If not, presumably the T-cell exits and carries on to another tissue to survey that one.
What is/are the antigen presenting cell(s) 
Macrophage lineage cells of the CNS and antigen presentation

MG
This term is usually reserved for cells exhibiting a branching, ramified morphology that reside throughout the CNS parenchyma within the confines of the glia limitans ( Figure 1 , population 1). They constitutively express CD1 l b (Mac-1) and, at low level, CD45 (leucocyte common antigen) molecules [8, 9] and are the resident 'macrophage' of the CNS. Foot processes of a minority of these cells that are close to vessels may contribute to the glia limitans [lo] . Most MG stay of host type in irradiation bone marrow chimaeras [9, 11] ; that is, they are irradiation-resistant and turnover is minimal, at least in the non-inflamed CNS. As illustrated in Table 1 Volume 25
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Other CNS macrophages The other main populations of macrophages in the CNS are found within the meninges and in the choroid plexus, again in an essentially perivascular location. It is important to note, however, that the anatomical structures of and around vessels of the meninges and the choroid plexus are quite distinct from those vessels around which classic CNS PVC are found [IS] .
In rats these macrophages stain with a number of monoclonal antibodies known to label normal macrophages, including ED1 (that recognizes a CD68-like antigen) and OX42 (against a shared determinant on rat C D l l b and CDllc) [17, 18] . Those within the meninges at least are highly irradiation-sensitive and turn over rapidly (in days) to be replaced by donor cells in irradiation bone marrow chimaeras. The vascular association of this type of CNS macrophage as well as the classic PVC are illustrated schematically in Figure 1 , population 2.
The use of irradiation bone marrow chimaeras and passively transferred EAE has been used to investigate the role of these various cell types in CNS antigen presentation [12, 15, 19] . In these studies, CD4' encephalitogenic myelin ranted. We adopted a novel approach to assess the immunological function of MG involving, first, the characterization of a distinct flow cytometric phenotype for MG in adult CNS tissue that enabled MG to be distinguished from all other types of CNS macrophages [9] , and second, the isolation of these different cell types in pure form by flow cytometric sorting to allow direct ex vivo assessment of APC function for encephalitogenic CD4' T-cell responses [18] . 
MG induce CD4' T-cell final effector function and death by apoptosis
Initial studies showed that the 'other' CNS macrophage populations isolated from the normal CNS (Figure 1 , population 2), were effective APC for CD4' MBP-reactive T-cell lines, inducing T-cell proliferation and interleukin 2 (IL-2) secretion. MG from the normal CNS were consistently poor on both counts, although this might be explained by a lack of MHC class I1 expression, present on only around 5% of freshly isolated MG but on 15% of other CNS macrophages [18] . The outcome of a series of experiments in which MHC class 11' MG were used instead and compared with other CNS macrophages from the normal CNS as well as irradiated lymph node cells as 'professional APC' control are summarized in Table 2 ( 
see also [S]).
The most striking result was that MG supported a degree of T-cell activation manifested as a rapid increase in the size of responding T-cells, in expression of the CD25 (IL-2Ra chain) and OX40 activation molecules, as well as in the readout of effector function involving production of the pro-inflammatory and potentially tissue-damaging cytokines tumour necrosis factor and interferon y (IFN-y) . However, no T-cell proliferation or IL-2 production was detected and the T-cells in these cultures went on to die by apoptosis. Apoptosis was preventable by the addition of exogenous IL-2 but although it acted as a 'survival factor' for the T-cells, it still did not enable the T-cells to proliferate, distinguishing this mechanism from that of anergy resulting from the lack of appropriate co-stimulation [25] . Moreover, even if the T-cells were rescued from apoptosis by IL-2, they were subseVolume 25 quently refractory to re-stimulation by crosslinking through the T-cell receptor. The 'other' CNS macrophages, isolated in the same way from adult CNS tissue, behaved identically with lymph node cell APC used as a positive control, essentially confirming the above-mentioned studies in vivo that demonstrated the APC potential of these populations of CNS macrophages [12] .
A new role for tissue-resident macrophages
This result, although an unexpected one at first glance given the prevailing view in the literature that MG are important for potentiation and perpetuation of T-cell responses in the CNS [26, 27] , is perhaps better viewed in the context of what actually seems to happen in vivo in the CNS. The following observations are instructive.
1. T h e observed paucity of activated or proliferating T-cells in the parenchyma of inflamed CNS [28] in which a network of MHC class 11' MG can normally be found.
MG constitutively express MHC class I1
most highly in the EAE-resistant Brown Norway rat strain [29] .
3. Intra-CNS administration of IFN-y, although strongly up-regulating MG MHC class I1 expression, inhibits or reduces the severity of 677 Table 2 Comparison of APC praperties of MG, other CNS macrophages and normal lymphoid APC MG were GvHD-activated, MHC class II', other CNS macrophages were from the normal CNS, and lymph node APC were 20 Gy-irradiated unfractionated lymph node cells. CNS- I would argue that it is in fact beneficial to the organism to terminate final effector cells in any tissue and particularly a sensitive one such as the CNS, and that the ability of MG to respond rapidly by MHC class I1 up-regulation might serve to promote this process. It is conceivable that comparable cell types in other tissues play a similar role. Currently we are seeking a mechanism for MG-induced T-cell apoptosis. Factor deprivation (i.e. lack of IL-2) is probably part of the story, but the inability to promote T-cell proliferation and continued 'anergy' in its presence suggests that the mechanism might be a more complex one and could include direct induction of apoptosis by the MG (FasLhumour necrosis factor?). By extension, what it is about MG that makes them different from those shorter-lived, vessel-associated 'other' CNS macrophages, is not known although ex vivo, neither express detectable B7. uB7.2 molecules so this is not the simple explanation thought likely (Table 2) . It is noteworthy, although perhaps not surprising, that other CNS macrophages perform admirably as APC for the secondary CD4' T-cell responses examined here, despite the absence of high levels of B7. UB7.2 molecules.
In summary, our experimental findings support a role for fixed resident macrophages (in this case, CNS MG) as at least one way of controlling T-cell responses in tissues, by inducing an immunological 'swan-song'. Such a mechanism could have a dual purpose. On the one hand it might contribute to the surveillance of tissues such as the CNS, through controlled release by T-cells of cytokines such as IFN-y and tumour necrosis factor, but not IL-2 in view of its proliferative potential. On the other hand it represents a novel way of terminating unwanted anti-self T-cell responses during the normal course of immune surveillance or within diseaseaffected inflamed tissues. 
